Bullish & Foolish
Full AGEN fundamentals All 466 on the Survival Watch

AGENAGENUS INC

Is Agenus struggling financially?

Yes, by its own account. Agenus told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Share sales and shelf filings

    Subsequent to quarter end, we received an additional $ 11.7 million in net proceeds from sales of common stock under our at-the-market equity offering program.

    Form 10-Q, filed 11 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$364.2M
Source filing
10-Q 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$18.7M

÷

Cash burned over the last 12 months

$77.2M

What Agenus told the SEC

…liquidity. Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the filing date of this Quarterly Report on Form 10-Q. The consolidated financial statements have been prepared assuming we will continue as a going concern…

AGENUS INC, Form 10-Q, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 50.7% share-count increase The company issued stock. Each share now owns 33.7% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • Cash burn is narrowing It is spending 66% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt